X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet   (GLPH)

Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 627.9
Mkt Cap Rs m 170,323
Vol '000 169.0
P/E X 14.2
P/CF X 17.5
EPS (TTM) Rs 44.1
% ch % -0.1
No. of shares m 271.28
% ch week % 4.0
% ch 1-mth % 4.4
% ch 12-mth % -32.5
52 week H/L Rs 993.0/568.0
(As on Sep 22, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs3515516128791,262 
Low Rs263301464752672 
Sales per share (Unadj.) Rs148.6185.1221.4244.4270.6 
Earnings per share (Unadj.) Rs17.223.220.117.524.9 
Diluted earnings per shareRs17.123.220.117.525.9 
Cash flow per share (Unadj.) Rs20.827.928.127.134.4 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs1.992.002.002.002.08 
Dividend yield (eoy) %0.70.50.40.20.2 
Book value per share (Unadj.) Rs88.8102.0110.0110.6151.3 
Adj. book value per shareRs88.5101.9110.0110.6157.4 
Shares outstanding (eoy) m270.53270.85271.22271.29282.16 
Bonus/Rights/Conversions  ESOS---- 
Price / Sales ratio x2.12.32.43.33.6 
Avg P/E ratio x17.918.426.746.638.9 
P/CF ratio (eoy) x14.815.319.130.128.1 
Price / Book Value ratio x3.54.24.97.46.4 
Dividend payout %11.78.69.911.48.0 
Avg Mkt Cap Rs m83,053115,355145,889221,284272,778 
No. of employees `000NANANA9.510.0 
Total wages/salary Rs m6,2897,83010,26212,02413,782 
Avg. sales/employee Rs ThNMNMNM6,961.17,614.9 
Avg. wages/employee Rs ThNMNMNM1,262.51,374.8 
Avg. net profit/employee Rs ThNMNMNM499.0700.2 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m40,20650,12360,05266,29876,340 
Other income Rs m182108115219356 
Total revenues Rs m40,38850,23160,16766,51676,696 
Gross profit Rs m7,14410,15310,90810,22514,172 
Depreciation Rs m9791,2702,1682,6002,691 
Interest Rs m1,4661,6001,8861,9021,789 
Profit before tax Rs m4,8817,3906,9695,94310,048 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m2381,1071,5131,1903,028 
Profit after tax Rs m4,6436,2835,4564,7527,019 
Gross profit margin %17.820.318.215.418.6 
Effective tax rate %4.915.021.720.030.1 
Net profit margin %11.512.59.17.29.2 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m29,47237,26847,62753,23359,096 
Current liabilities Rs m19,01722,01429,49237,11340,018 
Net working cap to sales %26.030.430.224.325.0 
Current ratio x1.51.71.61.41.5 
Inventory Days Days7261577075 
Debtors Days Days113119131138119 
Net fixed assets Rs m24,24827,68230,35732,70439,075 
Share capital Rs m271271271271282 
"Free" reserves Rs m15,78919,33821,41517,56330,281 
Net worth Rs m24,01627,63029,83330,00342,703 
Long term debt Rs m13,12519,20324,28725,74424,873 
Total assets Rs m54,66071,71086,33696,875111,026 
Interest coverage x4.35.64.74.16.6 
Debt to equity ratio x0.50.70.80.90.6 
Sales to assets ratio x0.70.70.70.70.7 
Return on assets %11.211.08.56.97.9 
Return on equity %19.322.718.315.816.4 
Return on capital %17.119.216.414.117.5 
Exports to sales %13.411.911.744.843.3 
Imports to sales %0.91.71.07.17.4 
Exports (fob) Rs m5,4065,9577,03929,72033,044 
Imports (cif) Rs m3478585794,6805,672 
Fx inflow Rs m5,6627,0078,52831,29936,945 
Fx outflow Rs m2,3644,1353,64110,85661,066 
Net fx Rs m3,2982,8724,88820,443-24,122 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 8,044 6,479 8,537 4,817 3,449 
From Investments Rs m -2,778 -4,641 -3,681 -5,400 -8,802 
From Financial Activity Rs m -3,614 1,952 -980 1,992 6,986 
Net Cashflow Rs m 1,252 2,851 1,896 -311 934 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   AJANTA PHARMA  VENUS REMEDIES  PIRAMAL ENTERPRISES  ASTRAZENECA PHARMA  TTK HEALTHCARE  

Compare GLENMARK PHARMA With:   AJANTA PHARMA  VENUS REMEDIES  PIRAMAL ENTERPRISES  ASTRAZENECA PHARMA  TTK HEALTHCARE  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Views on news

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ADCOCK INGRAM COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS